|
|
12925 16th Avenue North
Plymouth, MN 55441 USA
phone:763-398-6200
fax:763.746.8016
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.placorinc.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Platelet Reactivity Testing |
|
| Management |
| Bill Haworth, President & CEO |
| |
|
|
| |
|
| Keywords |
| methodology, fingerprick, cardiovascular, platelet, cardiologists |
|
|
|
| Description |
|
PlaCor is a development stage company specializing in technology to help physicians evaluate the effects of aspirin, Plavix and other anti-platelet drugs. |
|
| Products / Services |
PlaCor's Platelet Reactivity Testing (PRT) is designed to evaluate the effects of anti-platelet medications intended to inhibit the clot formation that can cause heart attacks and strokes. It has potential benefits for the patients at increased risk for heart attack or stroke: those who have little or no response to aspirin and Plavix.
|
|
| Technology / Differentiation |
| Antiplatelet agents inhibit platelets from sticking together and initiating the clotting process. Most testing methods determine how "sticky" (or reactive) platelets are. PlaCor's PRTTM (Platelet Reactivity Test) is designed to be a point-of-care device that can be easily operated by non-laboratory personnel |
|
| Market / Customers |
PlaCor's customers are the at least 48 million people currently on chronic aspirin or aspirin-plus-Plavix therapy to prevent heart attack, strokes and stent thrombosis. Measuring the effects of anti-platelet therapy is estimated to be a $1.6 billion dollar enterprise in the U.S. alone.
|
|
| Status |
| PlaCor Inc. is currently continuing research work with PRT. The company anticipates receiving approval to sell the instrument in 2008. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members